Valuation: Telix Pharmaceuticals Limited

Market Cap 5.63B 3.89B 3.41B 3.15B 2.93B 5.53B 368B 37.73B 14.65B 182B 14.62B 14.3B 633B P/E 2026 *
433x
P/E 2027 * 87.4x
Enterprise Value 6.04B 4.18B 3.65B 3.37B 3.15B 5.93B 395B 40.47B 15.71B 195B 15.69B 15.34B 679B EV / Sales 2026 *
4.41x
EV / Sales 2027 * 3.79x
Free-Float
83.23%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day+3.65%
1 week+9.25%
Current month+3.65%
1 month+31.99%
3 months+30.19%
6 months+51.28%
Current year+53.44%
1 week 15.14
Extreme 15.14
17.24
1 month 12.17
Extreme 12.17
17.24
Current year 8.26
Extreme 8.26
17.24
1 year 8.26
Extreme 8.26
25.87
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 2017-01-02
Director of Finance/CFO 60 2022-07-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 2017-01-02
Chairman 66 2026-02-02
Director/Board Member 68 2018-06-18
Date Insider Type Main position Quantity % Market Cap.
06-10Buy

Director

10,200 0.0030%
05-25Free

Director

23,139 0.0068%
05-25Free

Founder

339,845 0.1001%
Change 5-day change 1-year change 3-year change Capi.($)
+3.56%+9.25%-28.60%+54.54% 3.78B
+1.15%+5.94%-3.40%+2.32% 46.62B
-2.77%+10.48%+409.05%+600.11% 40.95B
-0.03%+12.81%+22.61%-14.04% 32.26B
-1.73%+3.20%+17.72%+59.83% 32.24B
-3.29%+7.98%+14.01%+29.96% 25.53B
+1.15%+11.79% - - 16.38B
-0.96%+11.85%+68.73%+120.51% 15.27B
+0.56%+5.09%+13.43%+17.88% 13.61B
-1.74%+4.34%+100.68%+93.25% 13.34B
Average -0.40%+8.15%+68.25%+107.15% 24B
Weighted average by Cap. -0.83%+7.80%+92.66%+136.22%

Financials

2026 *2027 *
Net sales 1.37B 947M 829M 765M 714M 1.35B 89.55B 9.18B 3.56B 44.19B 3.56B 3.48B 154B 1.6B 1.11B 971M 896M 836M 1.58B 105B 10.75B 4.17B 51.76B 4.17B 4.07B 180B
Net income 11.94M 8.26M 7.23M 6.67M 6.23M 11.73M 781M 80.06M 31.08M 385M 31.03M 30.34M 1.34B 57.75M 39.95M 34.97M 32.28M 30.11M 56.74M 3.78B 387M 150M 1.86B 150M 147M 6.49B
Net Debt 408M 282M 247M 228M 213M 401M 26.7B 2.74B 1.06B 13.18B 1.06B 1.04B 45.91B 447M 310M 271M 250M 233M 440M 29.27B 3B 1.16B 14.44B 1.16B 1.14B 50.31B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
26-06-30 A$17.17 +3.53% 735,978
26-06-30 A$16.58 +2.54% 2,538,305
26-06-29 A$16.17 +5.48% 2,508,105
26-06-26 A$15.33 -2.23% 1,329,596
26-06-25 A$15.68 -0.32% 1,745,963
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
16.58AUD
Average target price
23.44AUD
Spread / Average Target
+41.34%

Quarterly revenue - Rate of surprise